BHCM
ATXS

Brevan Howard Capital Management’s Astria Therapeutics ATXS Stock Holding History

Brevan Howard Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,400
Closed -$97.6K – 1786
2025
Q3 		$97.6K Buy
+13,400
New +$90.7K ﹤0.01% 1866

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's ATXS Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 13,400 shares — an estimated $97.6K sold.

Brevan Howard Capital Management first reported a position in ATXS in Q3 2025 and held it in 1 quarter. The position peaked at $97.6K in Q3 2025. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 13,400 Astria Therapeutics shares in Q4 2025, an estimated $97.6K.
  • Brevan Howard Capital Management first reported a position in Astria Therapeutics in Q3 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's Astria Therapeutics position peaked at $97.6K in Q3 2025.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.